The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Open accessThe DOI matches its Crossref record; 452 of the 457 references it cites were found in a registry or an index.
Abstract
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs. This hypothesis was based on the discovery that fibril-free synthetic preparations of AβOs were potent CNS neurotoxins that rapidly inhibited long-term potentiation and, with time, caused selective nerve cell death (Lambert et al., 1998). The mechanism was attributed to disrupted signaling involving the tyrosine-protein kinase Fyn, mediated by an unknown toxin receptor. Over 4,000 articles concerning AβOs have been published since then, including more than 400 reviews. AβOs have been shown to accumulate in an AD-dependent manner in human and animal model brain tissue and, experimentally, to impair learning and memory and instigate major facets of AD neuropathology, including tau pathology, synapse deterioration and loss, inflammation, and oxidative damage. As reviewed by Hayden and Teplow in 2013, the AβO hypothesis "has all but supplanted the amyloid cascade." Despite the emerging understanding of the role played by AβOs in AD pathogenesis, AβOs have not yet received the clinical attention given to amyloid plaques, which have been at the core of major attempts at therapeutics and diagnostics but are no longer regarded as the most pathogenic form of Aβ. However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful disease modifying therapy can be envisioned. Ensuring that lessons learned from recent, late-stage clinical failures are applied appropriately throughout therapeutic development will further enable the likelihood of a successful therapy in the near-term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig.1 AβOs, not Aβ monomers or fibrils, instigate the neuron damage leading to dementia. Following cleavage from the membrane, Aβ peptides aggregate to form AβOs, some of which further aggregate to fibrils and some of which instigate the neuron damage leading to dementia. Reprinted with Jannis Productions permissions from the “Progress Report on Alzheimer’s Disease 2004-2005” (ed. AB Rodgers), NIH Publication Number: 05-5724. Digital images produced by Stacy Jannis and Rebekah Fredenburg of Jannis Productions [455].](https://figures.cochat.ai/paper-figures/f6b42a17775e4881b942c99d83b0c0fa/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-1.jpg)
![Fig.2 AβOs instigate multiple facets of AD-neuropathology. Observed in various culture and animal models. Reprinted by permission from Springer Nature: Acta Neuropathol, 129(2): 183-206, “Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis” by Viola KL and Klein WL. Copyright 2015 Springer Nature [200].](https://figures.cochat.ai/paper-figures/4c12da5f31934b84a9263cc86d9b1ffd/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-2.jpg)

![Fig.4 AβOs can be divided into two classes based on their temporal, spatial, and structural relationships to amyloid plaques as well as their ability to cause memory dysfunction. Type 1 AβOs (aka “peak 1” or HMW) are thought to be associated with memory impairment, while type 2 AβOs (aka “peak 2” or LMW) are not. Only type 2 AβOs are associated with amyloid plaques. Reprinted from “Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration” by Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, and Ashe KH. This was published in Cell Rep, 2015, 11(11): 1760-1771, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [119].](https://figures.cochat.ai/paper-figures/c5448ccd6aa14c24a04007d7a6986c4e/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-4.jpg)
![Fig.5 Only high-molecular weight AβOs are capable of binding cultured hippocampal neurons. Synthetic AβOs were divided into high and low molecular weight populations using 50 kDa molecular weight cutoff ultrafiltration (A-B) or size exclusion chromatography (D-F) and incubated with cultured hippocampal neurons. Only high-molecular weight AβOs bind neurons (A, E); no binding of low-molecular weight AβOs was evident (B, F). Scale bar = 40μm. Reprinted from “Synaptic targeting by Alzheimer’s-related amyloid beta oligomers” by Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, and Klein WL. This was published in J Neurosci, 2004, 24(45): 10191-10200, copyright 2004; permission conveyed through Copyright Clearance Center, Inc. [16].](https://figures.cochat.ai/paper-figures/16de889766c74140a8a5dc196a8cc4d2/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-5.jpg)
![Fig.6 PrPc mediates AβO toxicity through mGluR5, Fyn kinase, and NMDARs. Downstream consequences of the pathway include calcium dyshomeostasis, tau hyperphosphorylation, and synaptic dysfunction and loss. Reprinted from “Fyn kinase inhibition as a novel therapy for Alzheimer’s disease” by Nygaard HB, van Dyck CH, and Strittmater SM. This was published in Alzheimers Res Ther, 2014, 6(1): 8, under the terms of the Creative Commons Attribution License (CC BY) [227].](https://figures.cochat.ai/paper-figures/f727ef34b3b345d8b849289bdb182350/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-6.jpg)
![Fig.7 AβOs induce membrane re-distribution of NKAα3 subunit resulting its downregulation and excessive Ca++ buildup. A hypothesized early event in AβO-induced neuronal damage is binding to NKAα3 on neuronal membranes, causing restructuring of the NKAα3 docking station into toxic clusters of membrane proteins. Ultimately, this results in downregulation of NKAα3 on the neuronal surface and buildup of toxic Ca++. Adapted and reprinted from “Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station” by DiChiara T, DiNunno N, Clark J, Bu RL, Cline EN, Rollins MG, Gong Y, Brody DL, Sligar SG, Velasco PT, Viola KL, and Klein WL. This was published in Yale J Biol Med, 2017, 90(1): 45-61, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [199].](https://figures.cochat.ai/paper-figures/bd05d1a512054c909e16e461e4020c7c/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-7.jpg)
![Fig.8 A cumulative hypothesis for the development of sporadic AD. From De Felice, sporadic AD is hypothesized to be the result of the cumulative impact over a life-time of injuries to the brain and peripheral organs that results in increased AβO levels. Reprinted from “Alzheimer’s disease and insulin resistance: translating basic science into clinical applications” by De Felice FG. This was published in JClin Invest, 2013, 123(2): 531-539, under Free access [322].](https://figures.cochat.ai/paper-figures/24020b5bf03e43718e18004cdfcd4325/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-8.jpg)
![Fig.9 Putative therapeutic targets of the AβO pathogenic cascade. Including: 1) AβOs themselves; 2) AβO receptors; 3) signaling pathways; or 4) downstream effectors such as tau. Reprinted with permission of PNAS from “Toward a unified therapeutics approach targeting putative amyloid-beta oligomer receptors” by Overk CR and Masliah E. This was published in Proc Natl Acad Sci U S A, 2014, 111(38): 13680-13681 [392].](https://figures.cochat.ai/paper-figures/fd1348f91c8947ff93496ee3a5d93873/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-9.jpg)
![Fig.10 Mechanisms of Aβ-targeting phase III drugs in AD clinical trials. Drugs inhibiting AβO formation (A) or downstream consequences of toxic AβOs (B). Reprinted from “Alzheimer’s disease drug development pipeline: 2017” by Cummings J, Garam L, Mortsdorf T, Ritter A, and Zhong K. This was published in Alzheimers Dementia (N Y), 2017, 3(3): 367-384 [393], under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/) [393].](https://figures.cochat.ai/paper-figures/3fe1a59ed5324adab364ba96901a832d/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Soluble Aβ oligomers are the primary neurotoxic substances,131–133”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [131]
The cited source says what the claim attributes to it.
In the citing paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
In the citing paper
“The alternative “Aβ oligomer hypothesis”, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers (AβO)s rather than amyloid plaques as key players in AD pathogenesis [79,80,81].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedLarson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 277
RetractedRETRACTED: Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Reed, M. N., Hofmeister, J. J., Jungbauer, L., Welzel, A. T., Yu, C., Sherman, M. A., Lesné, S., LaDu, M. J., Walsh, D. M., Ashe, K. H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.007 · Cited by 131
RetractedAmar, F., Sherman, M. A., Rush, T., Larson, M., Boyle, G., Chang, L., Götz, J., Buisson, A., & Lesné, S. E. (2017) · Science Signaling · doi:10.1126/scisignal.aal2021 · Cited by 112
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 6×
“dence that AD is a transmissible prion-like disease [5], experimental data support the idea that A Os may spread from cell-to-cell and brain region-toregion in a prion-like manner.”
BackgroundInfluentialAmyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089 · cited 1×
“One potential mechanism is through microglia engulfment of synapses [285].”
BackgroundCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“This has been observed in the AD brain and in the brains of multiple animal models [7, 96, 154, 155].”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“A Os and plaques in these mice begin to accumulate extensively around 2 months of age [11, 92, 95].”
BackgroundDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
An active and socially integrated lifestyle in late life might protect against dementia
Fratiglioni, L., Paillard-Borg, S., & Winblad, B. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00767-7 · Cited by 2,135
The glymphatic system: a beginner's guide
Jessen, N. A., Munk, A. S. F., Lundgaard, I., & Nedergaard, M. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1581-6 · Cited by 2,075 · cited 3×
“The recently discovered glymphatic system functions to remove metabolic waste, including soluble proteins, from the CNS [360].”
BackgroundThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990 · cited 1×
“De Strooper and Karran propose that AD pathogenesis is not simply a neuron-centric, linear cascade initiated by A and leading to dementia, but rather a long, complex cellular phase consisting of feedback and feedforward responses of astrocytes, microglia, and vasculature [202].”
BackgroundThe toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“The sufficiency of A Os for pathogenesis was first indicated in an APP mouse (Indiana APP mutation V717F; outside of A 42 sequence) that showed synapse loss despite absence of plaques [86].”
BackgroundAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 1×
“Supporting evidence for the therapeutic value of BACE inhibitors comes from the protective A673T APP Icelandic mutation in humans, which reduces BACE processing of A PP [396, 397].”
BackgroundNatural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2005) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,687
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · cited 1×
“Overall, A Os have been found to instigate tau pathology [19, 51, 52], loss of neuronal polarity [53–55], impairment of axonal transport [56–58], deterioration of synapses [47, 55], oxidative stress [59–62], endoplasmic reticulum (ER) stress [18, 63, 64], insulin resistance [48, 65–67], neuroinflammation [19, 49, 68,…”
BackgroundRegulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Impairment of paravascular clearance pathways in the aging brain
Kress, B. T., Iliff, J. J., Xia, M., Wang, M., Wei, H. S., Zeppenfeld, D., Xie, L., Kang, H., Xu, Q., Liew, J. A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24271 · Cited by 1,521 · cited 2×
“Recent studies in mice show that glymphatic activity decreases sharply during aging, resulting in decreased A clearance from the brain [320].”
BackgroundProliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism
Cohen, S. I. A., Linse, S., Luheshi, L. M., Hellstrand, E., White, D. A., Rajah, L., Otzen, D. E., Vendruscolo, M., Dobson, C. M., & Knowles, T. P. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218402110 · Cited by 1,440
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188
Self-citationGong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061
Self-citationTargeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989
Self-citationMicroglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980
Wang, H.-X. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.12.1081 · Cited by 967
A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation
Dikic, I., Tokiwa, G., Lev, S., Courtneidge, S. A., & Schlessinger, J. (1996) · Nature · doi:10.1038/383547a0 · Cited by 954
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954
Self-citationDe Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · cited 4×
“A O-associated NMDAR activation [62] promotes Ca++ release from the ER, which leads”
BackgroundInfluentialSelf-citationKoffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850
Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835
Self-citationBomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J.-C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 832
Self-citationβ-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity
Wang, H.-Y., Lee, D. H. S., D'Andrea, M. R., Peterson, P. A., Shank, R. P., & Reitz, A. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5626 · Cited by 822
Signal Transduction Through Prion Protein
Mouillet-Richard, S., Ermonval, M., Chebassier, C., Laplanche, J. L., Lehmann, S., Launay, J. M., & Kellermann, O. (2000) · Science · doi:10.1126/science.289.5486.1925 · Cited by 805
Voluntary Exercise Decreases Amyloid Load in a Transgenic Model of Alzheimer's Disease
Adlard, P. A., Perreau, V. M., Pop, V., & Cotman, C. W. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0496-05.2005 · Cited by 804
APP mouse models for Alzheimer’s disease preclinical studies.
Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., Hardy, J., Vassar, R., Winblad, B., & Saido, T. C. (2017) · The EMBO Journal · doi:10.15252/embj.201797397 · Cited by 793
Structure–neurotoxicity relationships of amyloid β-protein oligomers
Ono, K., Condron, M. M., & Teplow, D. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905127106 · Cited by 770
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741
Self-citationThe Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
Sengupta, U., Nilson, A. N., & Kayed, R. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.035 · Cited by 740
Stranahan, A. M., Norman, E. D., Lee, K., Cutler, R. G., Telljohann, R. S., Egan, J. M., & Mattson, M. P. (2008) · Hippocampus · doi:10.1002/hipo.20470 · Cited by 737
Membrane protein assembly into Nanodiscs
Bayburt, T. H., & Sligar, S. G. (2010) · FEBS Letters · doi:10.1016/j.febslet.2009.10.024 · Cited by 727
Spangenberg, E. E., Lee, R. J., Najafi, A. R., Rice, R. A., Elmore, M. R. P., Blurton-Jones, M., West, B. L., & Green, K. N. (2016) · Brain · doi:10.1093/brain/aww016 · Cited by 695
Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686
Singh, B., Parsaik, A. K., Mielke, M. M., Erwin, P. J., Knopman, D. S., Petersen, R. C., & Roberts, R. O. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-130830 · Cited by 665
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons
Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A., Wisniewski, T., Gunther, E. C., & Strittmatter, S. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3178 · Cited by 662
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657
Self-citationAmyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628
Self-citationWidespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans
Johnson, V. E., Stewart, W., & Smith, D. H. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00513.x · Cited by 620
Townsend, M., Shankar, G. M., Mehta, T., Walsh, D. M., & Selkoe, D. J. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.103754 · Cited by 619
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587
Amyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · cited 1×
“receptor (p75NTR) [210], alpha7-nicotinic acetylcholine receptor ( 7nAChR) [211, 212], adrenergic receptors [213], the receptor for advanced glycation endproducts (RAGE) [214], calcium channels [215–217], leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2)/paired Ig-like receptor B (PirB) [64, 218, 21…”
BackgroundSelf-citationCrystal, H., Dickson, D., Fuld, P., Masur, D., Scott, R., Mehler, M., Masdeu, J., Kawas, C., Aronson, M., & Wolfson, L. (1988) · Neurology · doi:10.1212/wnl.38.11.1682 · Cited by 586
Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease
Peng, W., Achariyar, T. M., Li, B., Liao, Y., Mestre, H., Hitomi, E., Regan, S., Kasper, T., Peng, S., Ding, F., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.015 · Cited by 580 · cited 2×
“in A O accumulation [320, 321] (see discussion”
BackgroundUm, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568
Roh, J. H., Huang, Y., Bero, A. W., Kasten, T., Stewart, F. R., Bateman, R. J., & Holtzman, D. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004291 · Cited by 563
Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R. S., Harlan, J., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03407.x · Cited by 559
Alzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549 · cited 4×
“Since the systematic review conducted by Cummings and colleagues in January 2017 [393], Merck has halted its phase II and III trials of the BACE inhibitor verubescestat for lack of efficacy; a leading theory for this failure is the timing of treatment [399].”
BackgroundMethodInfluentialMainardi, M., Di Garbo, A., Caleo, M., Berardi, N., Sale, A., & Maffei, L. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00001 · Cited by 545
Karp, A., Paillard-Borg, S., Wang, H.-X., Silverstein, M., Winblad, B., & Fratiglioni, L. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000089919 · Cited by 542
Ma, Q.-L., Yang, F., Rosario, E. R., Ubeda, O. J., Beech, W., Gant, D. J., Chen, P. P., Hudspeth, B., Chen, C., Zhao, Y., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1071-09.2009 · Cited by 536
Hutchinson, E. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2985 · Cited by 532
Cohen, R. M., Rezai-Zadeh, K., Weitz, T. M., Rentsendorj, A., Gate, D., Spivak, I., Bholat, Y., Vasilevko, V., Glabe, C. G., Breunig, J. J., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3672-12.2013 · Cited by 531
Self-Assembly of Aβ 1 - 42 into Globular Neurotoxins
Chromy, B. A., Nowak, R. J., Lambert, M. P., Viola, K. L., Chang, L., Velasco, P. T., Jones, B. W., Fernandez, S. J., Lacor, P. N., Horowitz, P., et al. (2003) · Biochemistry · doi:10.1021/bi030029q · Cited by 522
Self-citationLee, S., Varvel, N. H., Konerth, M. E., Xu, G., Cardona, A. E., Ransohoff, R. M., & Lamb, B. T. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100265 · Cited by 522
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Aging renders the brain vulnerable to amyloid β-protein neurotoxicity
Guela, C., Wu, C.-K., Saroff, D., Lorenzo, A., Yuan, M., & Yankner, B. A. (1998) · Nature Medicine · doi:10.1038/nm0798-827 · Cited by 520 · cited 1×
“This resulted in microglial activation, neuronal loss, and tau phosphorylation [373, 374].”
BackgroundAmyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · cited 1×
“This elevation is opposite to the AD-dependent change measured in monomeric A levels, which decrease rather than increase [33].”
ResultDeleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5
Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., & Triller, A. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.029 · Cited by 468
Self-citationSynthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein
Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., Tapella, L., Colombo, L., Manzoni, C., Borsello, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911829107 · Cited by 466
Dineley, K. T., Westerman, M., Bui, D., Bell, K., Ashe, K. H., & Sweatt, J. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04125.2001 · Cited by 462
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442
Self-citationExcessive burden of lysosomal storage disorder gene variants in Parkinson’s disease
Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., Heutink, P., Shulman, J. M., International Parkinson’s Disease Genomics Consortium (IPDGC), Nalls, M. A., et al. (2017) · Brain · doi:10.1093/brain/awx285 · Cited by 433
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers
De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.029 · Cited by 432
Self-citationInteractions of pathological proteins in neurodegenerative diseases
Spires-Jones, T. L., Attems, J., & Thal, D. R. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1709-7 · Cited by 429
Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427
Na+-K+-ATPase-Mediated Signal Transduction: From Protein Interaction to Cellular Function
Xie, Z. (2003) · Molecular Interventions · doi:10.1124/mi.3.3.157 · Cited by 423
A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia
Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A., Kanemitsu, H., Takuma, H., Kuwano, R., Imagawa, M., Ataka, S., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21321 · Cited by 421
Lourenco, M. V., Clarke, J. R., Frozza, R. L., Bomfim, T. R., Forny-Germano, L., Batista, A. F., Sathler, L. B., Brito-Moreira, J., Amaral, O. B., Silva, C. A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.002 · Cited by 420
Self-citationPhosphorylation of Tau by Fyn: Implications for Alzheimer's Disease
Lee, G., Thangavel, R., Sharma, V. M., Litersky, J. M., Bhaskar, K., Fang, S. M., Do, L. H., Andreadis, A., Van Hoesen, G., & Ksiezak-Reding, H. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4162-03.2004 · Cited by 414
Kim, T., Vidal, G. S., Djurisic, M., William, C. M., Birnbaum, M. E., Garcia, K. C., Hyman, B. T., & Shatz, C. J. (2013) · Science · doi:10.1126/science.1242077 · Cited by 410
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 410
Brain amyloid-β oligomers in ageing and Alzheimer’s disease
Lesné, S. E., Sherman, M. A., Grant, M., Kuskowski, M., Schneider, J. A., Bennett, D. A., & Ashe, K. H. (2013) · Brain · doi:10.1093/brain/awt062 · Cited by 409
Cheng, I. H., Scearce-Levie, K., Legleiter, J., Palop, J. J., Gerstein, H., Bien-Ly, N., Puolivaöli, J., Lesné, S., Ashe, K. H., Muchowski, P. J., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701078200 · Cited by 407
The amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
Tomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5825-09.2010 · Cited by 396
Self-citationJimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383
Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370 · cited 1×
“In a potential turning point, an antibody that can engage A Os, Aducanumab, has recently shown modest therapeutic benefit in early clinical trials [104, 105].”
BackgroundMcClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 361
Tau Aggregation and Its Interplay with Amyloid-β
Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359
Preparation and Characterization of Neurotoxic Tau Oligomers
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Jackson, G. R., & Kayed, R. (2010) · Biochemistry · doi:10.1021/bi1016233 · Cited by 359 · cited 1×
“A Os even can seed the formation of tau oligomers, which are thought to be the most toxic form of tau [294].”
BackgroundOda, T., Wals, P., Osterburg, H. H., Johnson, S. A., Pasinetti, G. M., Morgan, T. E., Rozovsky, I., Stine, W. B., Snyder, S. W., Holzman, T. F., et al. (1995) · Experimental Neurology · doi:10.1006/exnr.1995.1080 · Cited by 352
Manczak, M., & Reddy, P. H. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds360 · Cited by 348
Yang, T., Li, S., Xu, H., Walsh, D. M., & Selkoe, D. J. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1698-16.2016 · Cited by 347
How does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
Alzheimer’s disease and insulin resistance: translating basic science into clinical applications
De Felice, F. G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64595 · Cited by 330
Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
Koffie, R. M., Hashimoto, T., Tai, H.-C., Kay, K. R., Serrano-Pozo, A., Joyner, D., Hou, S., Kopeikina, K. J., Frosch, M. P., Lee, V. M., et al. (2012) · Brain · doi:10.1093/brain/aws127 · Cited by 327
Klyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5161-07.2008 · Cited by 321 · cited 1×
“Long-term potentiation (LTP) and long-term depression, the electrophysiological underpinnings of memory formation, are disrupted by A Os both ex vivo and in vivo [26, 36, 37, 40, 41].”
BackgroundFyn inhibition rescues established memory and synapse loss in Alzheimer mice
Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314 · cited 1×
“Pre-clinically, it was found to reverse cognitive deficits in AD mice [412].”
BackgroundMonoclonal antibodies that target pathological assemblies of Aβ
Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314
Self-citationType 3 diabetes is sporadic Alzheimer׳s disease: Mini-review
de la Monte, S. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.008 · Cited by 313
Alexander, A. G., Marfil, V., & Li, C. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00279 · Cited by 310 · cited 1×
“for learning and memory impairments [387].”
Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls
Esparza, T. J., Zhao, H., Cirrito, J. R., Cairns, N. J., Bateman, R. J., Holtzman, D. M., & Brody, D. L. (2013) · Annals of Neurology · doi:10.1002/ana.23748 · Cited by 306
The Metal Theory of Alzheimer's Disease
Bush, A. I. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129011 · Cited by 305
Temporal memory deficits in Alzheimer’s mouse models: Rescue by genetic deletion of BACE1
Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., Vassar, R., & Disterhoft, J. F. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04551.x · Cited by 298
Self-citationApolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide
Hashimoto, T., Serrano-Pozo, A., Hori, Y., Adams, K. W., Takeda, S., Banerji, A. O., Mitani, A., Joyner, D., Thyssen, D. H., Bacskai, B. J., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1542-12.2012 · Cited by 294
Sadleir, K. R., Kandalepas, P. C., Buggia-Prévot, V., Nicholson, D. A., Thinakaran, G., & Vassar, R. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1558-9 · Cited by 294
Beta-amyloid deposition in chronic traumatic encephalopathy
Stein, T. D., Montenigro, P. H., Alvarez, V. E., Xia, W., Crary, J. F., Tripodis, Y., Daneshvar, D. H., Mez, J., Solomon, T., Meng, G., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1435-y · Cited by 291 · cited 1×
“A Os, specifically, have not yet been implicated in CTE, but CTE is associated with repetitive brain injury and amyloid plaques have been observed in CTE brain tissue [448].”
BackgroundZempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E., & Mandelkow, E. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.207 · Cited by 283
Aβ42 assembles into specific β-barrel pore-forming oligomers in membrane-mimicking environments
Serra-Batiste, M., Ninot-Pedrosa, M., Bayoumi, M., Gairí, M., Maglia, G., & Carulla, N. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605104113 · Cited by 280
Maezawa, I., Zimin, P. I., Wulff, H., & Jin, L.-W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.135244 · Cited by 278
Roselli, F., Tirard, M., Lu, J., Hutzler, P., Lamberti, P., Livrea, P., Morabito, M., & Almeida, O. F. X. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3034-05.2005 · Cited by 277
Amyloid β-protein oligomers and Alzheimer’s disease
Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276
Karran, E., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 275
CAKβ/Pyk2 Kinase Is a Signaling Link for Induction of Long-Term Potentiation in CA1 Hippocampus
Huang, Y.-Q., Lu, W.-Y., Ali, D. W., Pelkey, K. A., Pitcher, G. M., Lu, Y. M., Aoto, H., Roder, J. C., Sasaki, T., Salter, M. W., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00220-3 · Cited by 274
Frandemiche, M. L., De Seranno, S., Rush, T., Borel, E., Elie, A., Arnal, I., Lanté, F., & Buisson, A. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4261-13.2014 · Cited by 272 · cited 1×
“A Os also have been shown to induce tau-dependent microtubule severing [291], to disrupt tau translocation to excitatory synapses [292], and to stabilize microtubules, the latter leading to tau-dependent loss of spines and tau hyperphosphorylation [293].”
BackgroundWidespread aggregation and neurodegenerative diseases are associated with supersaturated proteins
Ciryam, P., Tartaglia, G. G., Morimoto, R. I., Dobson, C. M., & Vendruscolo, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.043 · Cited by 270
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270
A 3D human neural cell culture system for modeling Alzheimer's disease
Kim, Y. H., Choi, S. H., D'Avanzo, C., Hebisch, M., Sliwinski, C., Bylykbashi, E., Washicosky, K. J., Klee, J. B., Brüstle, O., Tanzi, R. E., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.065 · Cited by 269
Umeda, T., Tomiyama, T., Sakama, N., Tanaka, S., Lambert, M. P., Klein, W. L., & Mori, H. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22640 · Cited by 266
Self-citationNilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265
Hu, J., Akama, K. T., Krafft, G. A., Chromy, B. A., & Van Eldik, L. J. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01318-8 · Cited by 262
Physical Activity and Alzheimer’s Disease: A Systematic Review
Stephen, R., Hongisto, K., Solomon, A., & Lönnroos, E. (2017) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw251 · Cited by 262
Astrocytes Regulate Microglial Phagocytosis of Senile Plaque Cores of Alzheimer's Disease
DeWitt, D. A., Perry, G., Cohen, M., Doller, C., & Silver, J. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6738 · Cited by 261
Zn2+ interaction with Alzheimer amyloid beta protein calcium channels.
Arispe, N., Pollard, H. B., & Rojas, E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1710 · Cited by 256
Amyloid-β Receptors: The Good, the Bad, and the Prion Protein
Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.702704 · Cited by 256
Tran, H. T., LaFerla, F. M., Holtzman, D. M., & Brody, D. L. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0858-11.2011 · Cited by 255
Intraneuronal Aβ-Amyloid Precedes Development of Amyloid Plaques in Down Syndrome
Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., & Troncoso, J. C. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0489-iaapdo · Cited by 248
McColl, G., Roberts, B. R., Pukala, T. L., Kenche, V. B., Roberts, C. M., Link, C. D., Ryan, T. M., Masters, C. L., Barnham, K. J., Bush, A. I., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-57 · Cited by 247
Podlisny, M. B., Tolan, D. R., & Selkoe, D. J. (1991) · PubMed Central · Cited by 244
Hallmarks of Alzheimer’s Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain
Espuny-Camacho, I., Arranz, A. M., Fiers, M., Snellinx, A., Ando, K., Munck, S., Bonnefont, J., Lambot, L., Corthout, N., Omodho, L., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.001 · Cited by 244
Tabner, B. J., El-Agnaf, O. M. A., Turnbull, S., German, M. J., Paleologou, K. E., Hayashi, Y., Cooper, L. J., Fullwood, N. J., & Allsop, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500238200 · Cited by 242
Nichol, K. E., Poon, W. W., Parachikova, A. I., Cribbs, D. H., Glabe, C. G., & Cotman, C. W. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-13 · Cited by 239
Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease
Pooler, A. M., Polydoro, M., Maury, E. A., Nicholls, S. B., Reddy, S. M., Wegmann, S., William, C., Saqran, L., Cagsal-Getkin, O., Pitstick, R., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0199-x · Cited by 236
Mc Donald, J. M., Savva, G. M., Brayne, C., Welzel, A. T., Forster, G., Shankar, G. M., Selkoe, D. J., Ince, P. G., & Walsh, D. M. (2010) · Brain · doi:10.1093/brain/awq065 · Cited by 234
Alzheimer's Disease-Like Pathology Induced by Amyloid-β Oligomers in Nonhuman Primates
Forny-Germano, L., Lyra e Silva, N. M., Batista, A. F., Brito-Moreira, J., Gralle, M., Boehnke, S. E., Coe, B. C., Lablans, A., Marques, S. A., Martinez, A. M. B., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1353-14.2014 · Cited by 233
Self-citationRepurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease
Yarchoan, M., & Arnold, S. E. (2014) · Diabetes · doi:10.2337/db14-0287 · Cited by 231
Vella, L., Hill, A., & Cheng, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020173 · Cited by 230
Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta
Pigino, G., Morfini, G., Atagi, Y., Deshpande, A., Yu, C., Jungbauer, L., LaDu, M., Busciglio, J., & Brady, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901229106 · Cited by 227
Ochalek, A., Mihalik, B., Avci, H. X., Chandrasekaran, A., Téglási, A., Bock, I., Giudice, M. L., Táncos, Z., Molnár, K., László, L., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0317-z · Cited by 225 · cited 2×
“These studies indicate that familial AD and sporadic AD iPSCs exhibit differential manifestations of ER stress [376] and A 40 accumulation [377], indicating that different therapeutics may be effective for patient subsets.”
BackgroundLeon, W. C., Canneva, F., Partridge, V., Allard, S., Ferretti, M. T., DeWilde, A., Vercauteren, F., Atifeh, R., Ducatenzeiler, A., Klein, W., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1349 · Cited by 221
Self-citationMagdesian, M. H., Carvalho, M. M. V. F., Mendes, F. A., Saraiva, L. M., Juliano, M. A., Juliano, L., Garcia-Abreu, J., & Ferreira, S. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707108200 · Cited by 221
Neurotoxic protein oligomers — what you see is not always what you get
Bitan, G., Fradinger, E. A., Spring, S. M., & Teplow, D. B. (2005) · Amyloid · doi:10.1080/13506120500106958 · Cited by 221 · cited 1×
“Because A has been found to aggregate in sodium dodecyl sulfate (SDS) [28], some investigators have concluded that the quickly forming A Os seen in SDS-PAGE are experimental artifacts [29, 30].”
BackgroundWilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219
High-speed atomic force microscopy reveals structural dynamics of amyloid β 1–42 aggregates
Watanabe-Nakayama, T., Ono, K., Itami, M., Takahashi, R., Teplow, D. B., & Yamada, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524807113 · Cited by 216
Selective neuronal degeneration induced by soluble oligomeric amyloid beta‐protein
Kim, H., Chae, S., Lee, D., Chromy, B., Cheol Lee, S., Park, Y., Klein, W. L., Krafft, G. A., & Hong, S. (2003) · The FASEB Journal · doi:10.1096/fj.01-0987fje · Cited by 210
Self-citationNimmrich, V., Grimm, C., Draguhn, A., Barghorn, S., Lehmann, A., Schoemaker, H., Hillen, H., Gross, G., Ebert, U., & Bruehl, C. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4771-07.2008 · Cited by 210
Ion Channel Formation by Amyloid-β42 Oligomers but Not Amyloid-β40 in Cellular Membranes
Bode, D. C., Baker, M. D., & Viles, J. H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.762526 · Cited by 209
Pham, E., Crews, L., Ubhi, K., Hansen, L., Adame, A., Cartier, A., Salmon, D., Galasko, D., Michael, S., Savas, J. N., et al. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07719.x · Cited by 206
Klyubin, I., Walsh, D. M., Shankar, G. M., Townsend, M., Fadeeva, J. V., Betts, V., Podlisny, M. B., Cleary, J. P., Ashe, K. H., Rowan, M. J., et al. (2005) · Biochemical Society Transactions · doi:10.1042/bst20051087 · Cited by 206
Andreev, J., Galisteo, M. L., Kranenburg, O., Logan, S. K., Chiu, E. S., Okigaki, M., Cary, L. A., Moolenaar, W. H., & Schlessinger, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102307200 · Cited by 205
Fu, A. K. Y., Hung, K.-W., Huang, H., Gu, S., Shen, Y., Cheng, E. Y. L., Ip, F. C. F., Huang, X., Fu, W.-Y., & Ip, N. Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405803111 · Cited by 201 · cited 1×
“receptor A (EphA4) [208, 209], p75 neurotrophin”
Fyn kinase inhibition as a novel therapy for Alzheimer’s disease
Nygaard, H. B., van Dyck, C. H., & Strittmatter, S. M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt238 · Cited by 200
Autophagic/lysosomal dysfunction in Alzheimer’s disease
Orr, M. E., & Oddo, S. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt217 · Cited by 199
β-Amyloid impairs axonal BDNF retrograde trafficking
Poon, W. W., Blurton-Jones, M., Tu, C. H., Feinberg, L. M., Chabrier, M. A., Harris, J. W., Jeon, N. L., & Cotman, C. W. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.012 · Cited by 198
Maloney, J. A., Bainbridge, T., Gustafson, A., Zhang, S., Kyauk, R., Steiner, P., van der Brug, M., Liu, Y., Ernst, J. A., Watts, R. J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589069 · Cited by 197
Brody, D. L., & Holtzman, D. M. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.020 · Cited by 195
Smith, D. P., Ciccotosto, G. D., Tew, D. J., Fodero-Tavoletti, M. T., Johanssen, T., Masters, C. L., Barnham, K. J., & Cappai, R. (2007) · Biochemistry · doi:10.1021/bi0620961 · Cited by 194
Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease
Viola, K. L., Sbarboro, J., Sureka, R., De, M., Bicca, M. A., Wang, J., Vasavada, S., Satpathy, S., Wu, S., Joshi, H., et al. (2015) · Nature Nanotechnology · doi:10.1038/nnano.2014.254 · Cited by 193
Self-citationAlberdi, E., Wyssenbach, A., Alberdi, M., Sánchez‐Gómez, M. V., Cavaliere, F., Rodríguez, J. J., Verkhratsky, A., & Matute, C. (2013) · Aging Cell · doi:10.1111/acel.12054 · Cited by 190
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190 · cited 3×
“Such antibodies will be optimized by a better understanding of A O structure-toxicity relationships [101, 106–108], Besides development of A O-specific antibodies [89, 101, 109], other tactics are likely to improve the prospects of A -directed therapies.”
BackgroundInfluentialZhao, W.-Q., Santini, F., Breese, R., Ross, D., Zhang, X. D., Stone, D. J., Ferrer, M., Townsend, M., Wolfe, A. L., Seager, M. A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.057182 · Cited by 188 · cited 1×
“receptor (p75NTR) [210], alpha7-nicotinic acetylcholine receptor ( 7nAChR) [211, 212], adrenergic receptors [213], the receptor for advanced glycation endproducts (RAGE) [214], calcium channels [215–217], leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2)/paired Ig-like receptor B (PirB) [64, 218, 21…”
BackgroundClinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
Galasko, D., Bell, J., Mancuso, J. Y., Kupiec, J. W., Sabbagh, M. N., van Dyck, C., Thomas, R. G., Aisen, P. S., & Study, F. T. A. D. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000364 · Cited by 187
Systematic In Vivo Analysis of the Intrinsic Determinants of Amyloid β Pathogenicity
Luheshi, L. M., Tartaglia, G. G., Brorsson, A.-C., Pawar, A. P., Watson, I. E., Chiti, F., Vendruscolo, M., Lomas, D. A., Dobson, C. M., & Crowther, D. C. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050290 · Cited by 187
Podlisny, M. B., Walsh, D. M., Amarante, P., Ostaszewski, B. L., Stimson, E. R., Maggio, J. E., Teplow, D. B., & Selkoe, D. J. (1998) · Biochemistry · doi:10.1021/bi972029u · Cited by 186
Very long term studies of the seeding of β-amyloidosis in primates
Ridley, R. M., Baker, H. F., Windle, C. P., & Cummings, R. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0385-2 · Cited by 186
A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid
Savage, M. J., Kalinina, J., Wolfe, A., Tugusheva, K., Korn, R., Cash-Mason, T., Maxwell, J. W., Hatcher, N. G., Haugabook, S. J., Wu, G., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1675-13.2014 · Cited by 183
Figueiredo, C. P., Clarke, J. R., Ledo, J. H., Ribeiro, F. C., Costa, C. V., Melo, H. M., Mota-Sales, A. P., Saraiva, L. M., Klein, W. L., Sebollela, A., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0482-13.2013 · Cited by 183
Self-citationA central role for dityrosine crosslinking of Amyloid-β in Alzheimer’s disease
Al-Hilaly, Y. K., Williams, T. L., Stewart-Parker, M., Ford, L., Skaria, E., Cole, M., Bucher, W. G., Morris, K. L., Sada, A. A., Thorpe, J. R., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-83 · Cited by 183
Amyloid β Oligomers Disrupt Blood–CSF Barrier Integrity by Activating Matrix Metalloproteinases
Brkic, M., Balusu, S., Van Wonterghem, E., Gorlé, N., Benilova, I., Kremer, A., Van Hove, I., Moons, L., De Strooper, B., Kanazir, S., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0006-15.2015 · Cited by 182
Izzo, N. J., Staniszewski, A., To, L., Fa, M., Teich, A. F., Saeed, F., Wostein, H., Walko, T., Vaswani, A., Wardius, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111898 · Cited by 180 · cited 1×
“The Sigma-2 receptor antagonist blocks A O binding to cultured neurons and improves cognitive deficits in AD mouse models [203].”
BackgroundThe PI3K-Akt-mTOR pathway regulates Aβ oligomer induced neuronal cell cycle events
Bhaskar, K., Miller, M., Chludzinski, A., Herrup, K., Zagorski, M., & Lamb, B. T. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-14 · Cited by 177
Zahs, K. R., & Ashe, K. H. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.05.004 · Cited by 175
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Evans, A. C., & Initiative, A. T. A. D. N. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003956 · Cited by 175
Fitz, N. F., Cronican, A., Pham, T., Fogg, A., Fauq, A. H., Chapman, R., Lefterov, I., & Koldamova, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1051-10.2010 · Cited by 175
Supersaturation is a major driving force for protein aggregation in neurodegenerative diseases
Ciryam, P., Kundra, R., Morimoto, R. I., Dobson, C. M., & Vendruscolo, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.12.004 · Cited by 174
Noguchi, A., Matsumura, S., Dezawa, M., Tada, M., Yanazawa, M., Ito, A., Akioka, M., Kikuchi, S., Sato, M., Ideno, S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000208 · Cited by 173
Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease
Ferretti, M. T., Bruno, M. A., Ducatenzeiler, A., Klein, W. L., & Cuello, A. C. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.01.007 · Cited by 172
Self-citationPereira Diniz, L., Tortelli, V., Matias, I., Morgado, J., Bérgamo Araujo, A. P., Melo, H. M., Seixas da Silva, G. S., Alves-Leon, S. V., de Souza, J. M., Ferreira, S. T., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3351-16.2017 · Cited by 171
Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease
Bakota, L., & Brandt, R. (2016) · Drugs · doi:10.1007/s40265-015-0529-0 · Cited by 170
Imbalanced cholesterol metabolism in Alzheimer's disease
Xue-shan, Z., Peng, J., Wu, Q., Zhong, R., Li-hong, P., Tang, Z., Jiang, Z., Wang, G., & Liu, L. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.02.024 · Cited by 170
Tammineni, P., Ye, X., Feng, T., Aikal, D., & Cai, Q. (2017) · eLife · doi:10.7554/elife.21776 · Cited by 169
Tapia‐Rojas, C., Aranguiz, F., Varela‐Nallar, L., & Inestrosa, N. C. (2016) · Brain Pathology · doi:10.1111/bpa.12255 · Cited by 168
Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
Guerrero-Muñoz, M. J., Gerson, J., & Castillo-Carranza, D. L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00464 · Cited by 168
Research works printed but not linked: 4
- Meilandt, 2017, Characterization of the selective in vivo and in vitro binding properties of crenezumab: Insights into crenezumab’s unique mechanism of action, J Prev Alzheimers Dis, 4, 293
- Schneider, 2017, The anti-AB oligomer drug CT1812 for Alzheimer’s: Phase 1B/2A safety trial outcomes, J Prev Alzheimers Dis, 4, 317
- Catalano, 2017, Biomarker outcomes from the phase 1b/2a safety trial of the anti-AB oligomer drug CT1812 in Alzheimer’s patients, J Prev Alzheimers Dis, 4, 401
- Leslie, 2017, Phase II study to assess safety and target engagement of AMX0035, a novel combination therapy, in Alzheimer’s disease, Neurotherapeutics, 14, 825
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“121 – 124 Moreover, other genetic risk factors, 125,126 cardiovascular health issues (such as diabetes, hypercholesterolemia), and lifestyle factors (such as diet and sleep) 127 have also been extensively studied in recent years for their relationship with A β metabolism in SAD.”
BackgroundAlzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
Half a century of amyloids: past, present and future
Ke, P. C., Zhou, R., Serpell, L. C., Riek, R., Knowles, T. P. J., Lashuel, H. A., Gazit, E., Hamley, I. W., Davis, T. P., Fändrich, M., et al. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00199a · Cited by 568
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374
Metadata
- Authors
- Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Department of Neurobiology, Cognitive Neurology and Alzheimer’s Disease Center, International Institute for Nanotechnology, and Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA
- Corresponding author
- Klein, William L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S567-S610
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6004937
- OpenAlex
- W2809078375
- Cited by
- 870
- References
- 457
- Citations by year
- 2026: 72 · 2025: 109 · 2024: 99 · 2023: 133 · 2022: 123 · 2021: 123 · 2020: 119 · 2019: 74 · 2018: 17
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R41AG054337, T32AG020506)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Humans, Models, Neurological, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.